Delcath net income holds at $2.7 million in Q2 FY26; revenue rises 20.25% to $29.1 million vs Q2 FY25

• Delcath Systems posted Q2 revenue of $29.1 million, up 20.25% from a year earlier, led by HEPZATO KIT revenue of $27.1 million.
• Net income was $2.7 million, unchanged from the prior-year quarter, while gross margin widened 4 percentage points to 90%.
• Non-GAAP adjusted EBITDA fell 22.45% to $7.6 million; cash and investments totaled $95.9 million at June 30, with no debt.
• Active treatment centers rose to 31, with HEPZATO volume up about 30% year over year; the first patient was dosed in a global Phase 2 breast cancer trial.
• Raised 2026 revenue guidance to $104 million-$108 million, projecting at least 28% growth in HEPZATO KIT volume versus 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053902), on August 06, 2026, and is solely responsible for the information contained therein.